Chicago-Land, Illinois


Steven Davis

Invokana: Do the Benefits Really Outweigh the Risks?

Invokana, the first SGLT-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) to treat type 2 diabetes, caused concerns about cardiovascular injuries and kidney failure early on, within two years of the drug’s introduction to the market in […]

Steven Davis

Diabetes Drug Invokana Linked to Kidney Failure and Impairment

The treatment of diabetes is among the most common drug therapies in the U.S., and 21 million Americans took blood sugar lowering drugs in 2012, with more than 90 percent of those being treated for Type 2 diabetes. The U.S. […]